Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Anixa Biosciences
(NASDAQ:ANIX)
Intraday
$3.16
-0.07
[-2.17%]
15 minutes delayed
Get Report
Watch
Perks
Buy
Compare Brokers
$3.16
-0.07
[-2.17%]
Last update: 9:29AM
Get Real Time Here
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Anixa Biosciences Stock (NASDAQ:ANIX)
Anixa Biosciences Stock (NASDAQ: ANIX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, March 21, 2024
HC Wainwright & Co. Reiterates Buy on Anixa Biosciences, Maintains $12 Price Target
Benzinga Newsdesk
-
Mar 21, 2024, 6:33AM
Tuesday, March 12, 2024
Recap: Anixa Biosciences Q1 Earnings
Benzinga Insights
-
Mar 12, 2024, 5:45PM
Tuesday, February 13, 2024
HC Wainwright & Co. Reiterates Buy on Anixa Biosciences, Maintains $12 Price Target
Benzinga Newsdesk
-
Feb 13, 2024, 12:28PM
Monday, February 12, 2024
Anixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical Trial
Benzinga Newsdesk
-
Feb 12, 2024, 7:33AM
Tuesday, January 23, 2024
Anixa Biosciences Announces Japanese Patent On Ovarian Cancer Vaccine Technology
Benzinga Newsdesk
-
Jan 23, 2024, 8:06AM
Wednesday, December 20, 2023
Anixa Biosciences, A New Type Of Biotech Company: Could It Disrupt The Cancer Landscape?
Kimberly Adams
-
Dec 20, 2023, 1:19PM
Thursday, December 07, 2023
Anixa Biosciences Reveals Updated Data From Breast Cancer Vaccine Trial, Says 'Exceeded Expectations'
Vandana Singh
-
Dec 7, 2023, 9:58AM
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights
-
Dec 7, 2023, 8:07AM
HC Wainwright & Co. Reiterates Buy on Anixa Biosciences, Maintains $12 Price Target
Benzinga Newsdesk
-
Dec 7, 2023, 6:28AM
Wednesday, December 06, 2023
Anixa Biosciences And Cleveland Clinic Present New Data From Phase 1 Study Of Breast Cancer Vaccine; Report Antigen-Specific T Cell Responses Observed At All Dose Levels
Benzinga Newsdesk
-
Dec 6, 2023, 6:01PM
Anixa Biosciences To Host Conference Call This Evening To Discuss New Data From Ongoing Phase 1 Study Of Breast Cancer Vaccine
Benzinga Newsdesk
-
Dec 6, 2023, 4:19PM
Monday, November 27, 2023
Anixa Biosciences Announces European Patent On Ovarian Cancer Vaccine Technology
Benzinga Newsdesk
-
Nov 27, 2023, 8:44AM
Friday, October 13, 2023
Anixa Biosciences Completes Treatment Of First Patient Cohort In Ovarian Cancer CAR-T Clinical Trial
Benzinga Newsdesk
-
Oct 13, 2023, 8:35AM
Thursday, October 12, 2023
Board Member at Anixa Biosciences Exercises Options Worth $54K
Benzinga Insights
-
Oct 12, 2023, 11:01AM
Wednesday, October 11, 2023
Anixa Biosciences Director Acquires 16,000 Shares After Exercising Company Stock Options
Benzinga Insights
-
Oct 11, 2023, 11:00AM
Tuesday, October 03, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Oct 3, 2023, 2:37PM
Anixa Biosciences Announces Issuance Of Additional U.S. Patent For Ovarian Cancer Vaccine Technology
Benzinga Newsdesk
-
Oct 3, 2023, 8:34AM
Monday, September 18, 2023
HC Wainwright & Co. Reiterates Buy on Anixa Biosciences, Maintains $12 Price Target
Benzinga Newsdesk
-
Sep 18, 2023, 12:19PM
Tuesday, August 29, 2023
HC Wainwright & Co. Reiterates Buy on Anixa Biosciences, Maintains $12 Price Target
Benzinga Newsdesk
-
Aug 29, 2023, 6:12AM
Monday, August 28, 2023
Anixa Biosciences Announces Treatment Of Third Patient In Ovarian Cancer CAR-T Clinical Trial
Benzinga Newsdesk
-
Aug 28, 2023, 8:33AM
Monday, August 14, 2023
Anixa Biosciences Announces Invited Presentation On Ovarian Cancer CAR-T Therapy At The 8th Annual CAR-TCR Summit
Happy Mohamed
-
Aug 14, 2023, 8:58AM
Wednesday, August 09, 2023
Could Anixa Biosciences (NASDAQ: ANIX) Be Developing The Vaccine To End One Of The Deadliest Types Of Breast Cancer?
Faith Ashmore
-
Sponsored
Monday, August 07, 2023
Anixa Biosciences Announces Opening Of Enrollment For Keytruda Arm In Ongoing Breast Cancer Vaccine Clinical Trial
Happy Mohamed
-
Aug 7, 2023, 8:48AM
Tuesday, August 01, 2023
Chief Executive Officer at Anixa Biosciences Exercises Options Worth $144K
Benzinga Insights
-
Aug 1, 2023, 11:00AM
Anixa Biosciences Board Member Acquires 120,000 Shares After Exercising Company Stock Options
Benzinga Insights
-
Aug 1, 2023, 11:00AM
Friday, July 28, 2023
HC Wainwright & Co. Reiterates Buy on Anixa Biosciences, Maintains $12 Price Target
Benzinga Newsdesk
-
Jul 28, 2023, 9:42AM
Thursday, July 27, 2023
Anixa Biosciences Announces Notice Of Allowance Of Additional Patent On Ovarian Cancer Vaccine Technology
Happy Mohamed
-
Jul 27, 2023, 8:37AM
Monday, July 24, 2023
Anixa Biosciences And 2 Other Penny Stocks Insiders Are Aggressively Buying
Lisa Levin
-
Jul 24, 2023, 7:43AM
Wednesday, July 12, 2023
HC Wainwright & Co. Reiterates Buy on Anixa Biosciences, Maintains $12 Price Target
Benzinga Newsdesk
-
Jul 12, 2023, 6:07AM
Tuesday, July 11, 2023
Anixa Biosciences Announces Issuance of Canadian Patent For Its CAR-T Cancer Therapy Technology
Happy Mohamed
-
Jul 11, 2023, 8:51AM
Monday, June 19, 2023
6 Analysts Have This to Say About Anixa Biosciences
Benzinga Insights
-
Jun 19, 2023, 5:00PM
HC Wainwright & Co. Reiterates Buy on Anixa Biosciences, Maintains $12 Price Target
Benzinga Newsdesk
-
Jun 19, 2023, 4:05AM
Tuesday, May 23, 2023
The Latest Analyst Ratings for Anixa Biosciences
Benzinga Insights
-
May 23, 2023, 12:01PM
HC Wainwright & Co. Reiterates Buy on Anixa Biosciences, Maintains $12 Price Target
Benzinga Newsdesk
-
May 23, 2023, 6:17AM
Monday, May 22, 2023
Anixa Biosciences Announces Treatment Of Second Patient In Its Ovarian Cancer CAR-T Clinical Trial
Benzinga Newsdesk
-
May 22, 2023, 8:35AM
Tuesday, April 18, 2023
Expert Ratings for Anixa Biosciences
Benzinga Insights
-
Apr 18, 2023, 1:01PM
HC Wainwright & Co. Reiterates Buy on Anixa Biosciences, Maintains $12 Price Target
Benzinga Newsdesk
-
Apr 18, 2023, 6:25AM
Chardan Capital Reiterates Buy on Anixa Biosciences, Maintains $9 Price Target
Benzinga Newsdesk
-
Apr 18, 2023, 5:00AM
Monday, April 17, 2023
Anixa Biosciences And Cleveland Clinic Present Data For Phase 1 Study Of Breast Cancer Vaccine
Happy Mohamed
-
Apr 17, 2023, 1:36PM
Thursday, March 23, 2023
HC Wainwright & Co. Maintains Buy on Anixa Biosciences, Raises Price Target to $12
Benzinga Newsdesk
-
Mar 23, 2023, 6:51AM
Wednesday, March 22, 2023
Chardan Capital Maintains Buy on Anixa Biosciences, Raises Price Target to $9
Benzinga Newsdesk
-
Mar 22, 2023, 4:45AM
Tuesday, February 28, 2023
HC Wainwright & Co. Reiterates Buy on Anixa Biosciences, Maintains $11 Price Target
Benzinga Newsdesk
-
Feb 28, 2023, 6:08AM
Monday, February 27, 2023
Anixa Biosciences Announces Notice Of Allowance Of Additional Patent On Breast Cancer Vaccine Technology
Bill Haddad
-
Feb 27, 2023, 8:32AM
Thursday, February 23, 2023
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights
-
Feb 23, 2023, 4:31PM
Friday, December 23, 2022
Benzinga's Top Ratings Upgrades, Downgrades For December 23, 2022
Benzinga Insights
-
Dec 23, 2022, 10:00AM
Chardan Capital Initiates Coverage On Anixa Biosciences with Buy Rating, Announces Price Target of $8
Benzinga Newsdesk
-
Dec 23, 2022, 5:39AM
Friday, December 09, 2022
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights
-
Dec 9, 2022, 4:33PM
Thursday, December 08, 2022
Anixa Biosciences Announces Maximum Tolerated Dose Reached In Trial Of Preventative Breast Cancer Vaccine
Benzinga Newsdesk
-
Dec 8, 2022, 8:33AM
Wednesday, October 26, 2022
Anixa Biosciences Announces Commencement Of Phase 1b Trial Of Its Breast Cancer Vaccine At Cleveland Clinic
Benzinga Newsdesk
-
Oct 26, 2022, 8:39AM
Monday, October 10, 2022
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights
-
Oct 10, 2022, 5:51PM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch